GEN Exclusives

More »

GEN News Highlights

More »
Oct 30, 2012

EC Follows FDA and Approves Lilly’s Erectile Dysfunction Drug for BPH

  • The European Commission approved Eli Lilly’s Cialis 5 mg (tadalafil) for treating the signs and symptoms of benign prostatic hyperplasia (BPH). EU clearance adds a new indication for the drug in Europe, where Cialis has been approved since 2002 in various dose strengths as an on-demand treatment for erectile dysfunction (ED). Once-daily Cialis was approved for the ED indication in 2007.

    FDA approved Cialis 5 mg for the BPH indication a year ago, and also sanctioned Cialis 5 mg for once-daily in men who have both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.

    Cialis is Lilly’s fourth top-selling human drug, which made global sales of $482.1 million in the third quarter of 2012, up 3% on Q3 2011 sales. U.S. sales of Cialis were $205.7 million (up 22%) during Q3 2012, driven by higher prices and increased demand. Sales of Cialis outside the U.S. were, conversely, down 8% at $276.4 million, due to the unfavorable impact of foreign exchange rates. Global sales of Cialis for the year to date reached $1.4 billion, up about 2% the equivalent period in 2011. 

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »